Sarepta Therapeutics recently received FDA approval to resume shipments of ELEVIDYS for ambulatory patients after a temporary pause. The FDA’s recommendation to lift the voluntary hold on Elevidys marks a significant milestone for Sarepta Therapeutics, allowing the company to continue providing the gene therapy to patients in need. This decision follows a comprehensive review of […]